Y-Intercept (HK)’s Regencell Bioscience RGC Stock Holding History

Y-Intercept (HK)’s Portfolio RGC Stock Details RGC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-13,042	Closed	-$222K	–	1960
2025 Q2	$222K	Buy	+13,042	New	+$159K	0.01%	1439

Other funds holding RGC

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Squarepoint New York $85.1B AUM 20.93% 1-Year Est. Return

DCM

Discovery Capital Management South Norwalk, Connecticut $1.92B AUM 218.96% 1-Year Est. Return

XTX Topco George Town, Cayman Islands $5.75B AUM 30.56% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Vident Advisory Alpharetta, Georgia $11.7B AUM 37.32% 1-Year Est. Return

Jane Street New York $777B AUM 61.18% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

BNP Paribas Financial Markets Paris, France $206B AUM 31.61% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Y-Intercept (HK)'s RGC Position: Q3 2025 in Review

Y-Intercept (HK) sold out of Regencell Bioscience (RGC) in Q3 2025, closing a stake of 13,042 shares — an estimated $222K sold.

Y-Intercept (HK) first reported a position in RGC in Q2 2025 and held it in 1 quarter. The position peaked at $222K in Q2 2025. 16 funds tracked by Wall St. Rank hold RGC as of Q3 2025.

Y-Intercept (HK) reported no remaining Regencell Bioscience position as of Q3 2025 after selling out during the quarter.
Y-Intercept (HK) sold 13,042 Regencell Bioscience shares in Q3 2025, an estimated $222K.
Y-Intercept (HK) first reported a position in Regencell Bioscience in Q2 2025 and held it in 1 quarter.
Y-Intercept (HK)'s Regencell Bioscience position peaked at $222K in Q2 2025.
16 funds tracked by Wall St. Rank held Regencell Bioscience as of Q3 2025.

Based on Y-Intercept (HK)'s 13F filing for Q3 2025, filed 31 Oct 2025.